Key facts
- This page summarizes Lynx1 Capital Management LP's Form 4 filing for TScan Therapeutics, Inc. (TCRX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 30 Dec 2024, 16:15.
Lynx1 Capital Management LP - 26 Dec 2024 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TCRX
- Reported as of
- 26 Dec 2024
- Net transaction value
- +$30,000,000
- SEC form
- 4
- Accepted by SEC
- 30 Dec 2024, 16:15:18 UTC
- Prior SEC filing
- 16 Dec 2024
- Next SEC filing
- 31 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- Lynx1 Capital Management LP, By: Lynx1 Capital Management GP LLC, its general partner, By: /s/ Weston Nichols, Sole Member
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Lynx1 Capital Management LP filed Form 4 for TScan Therapeutics, Inc. (TCRX) on 30 Dec 2024.
Change
- Previous filing in this sequence was filed on 16 Dec 2024.
- Current net transaction value: +$30,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TCRX
transaction
Derivative
Pre-funded Warrant (right to buy)
Purchase
- Transaction value
- $30,000,000
- Shares
- +7,500,000
- Change %
- Price
- $4.00
- Shares after
- 7,500,000
- Date
- 26 Dec 2024
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 7,500,000
- Exercise price
- $0.000100
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after December 27, 2024, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the "Blocker"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable.
Footnote F2
The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.